

Molina Healthcare of Texas Prior Authorization Code Matrix Update

Effective: April 1, 2020

Molina is updating the Prior Authorization Code Matrix for April 1, 2020. This is notification only and does not determine if the benefit is covered by the member's plan. The following codes are being updated:

CPT/HCPC CODE	DESCRIPTION	Line of Business	MOLINA SERVICE CATEGORY	Update
95950	MONITORID AND LATERALIZATION SEIZURE FOCUS EEG	All Lines of Business	Neuropsychological and Psychological Tests	PA Update: Inactive codes [replaced by 95700, 95705 thru 95726]
95951	LOCALIZE CEREBRAL SEIZURE CABLE RADIO EEG VIDEO	All Lines of Business	Neuropsychological and Psychological Tests	PA Update: Inactive codes [replaced by 95700, 95705 thru 95726]
95953	ALIZE CEREBRAL SEIZURE CPTR PORTABLE EEG	All Lines of Business	Neuropsychological and Psychological Tests	PA Update: Inactive codes [replaced by 95700, 95705 thru 95726]
95956	MNTR SEIZURE CMPTR 16CHAN EEG ATNDEA 24 HR	All Lines of Business	Neuropsychological and Psychological Tests	PA Update: Inactive codes [replaced by 95700, 95705 thru 95726]
81528	ONCOLOGY COLORECTAL SCREENING QUAN 10 DNA MARKRS	Marketplace	Genetic Counseling & Testing	Removal of Codes/No PA required
0373T	ADAPT BHV TX PRCL MODIFICA J EA 15 MIN TECH TIME	Medicaid & Marketplace	Experimental & Investigational	PA Update moving from Experimental/Investigational to Behavioral Health
0362T	BEHAVIOR ID SUPPORT ASSMT EA 15 MIN TECH TIME	Medicaid & Marketplace	Behavioral Health, Mental Health, Alcohol and Chemical Dependency Services	Removal of Codes/No PA required
97151	BEHAVIOR ID ASSESSMENT BY PHYS QHP EA 15 MIN	Medicaid & Marketplace	Behavioral Health, Mental Health, Alcohol and Chemical Dependency Services	Removal of Codes/No PA required
97152	BEHAVIOR ID SUPPORT ASSMT BY 1 TECH EA 15 MIN	Medicaid & Marketplace	Behavioral Health, Mental Health, Alcohol and Chemical Dependency Services	Removal of Codes/No PA required
90291	Cytomegalovirus immune globulin (CMV-IgIV), human, for intravenous use	Medicaid & Marketplace	Healthcare Administered Drugs	Addition of Codes/PA required
90371	Hepatitis B immune globulin (HBIG), human,	Medicaid & Marketplace	Healthcare Administered Drugs	Addition of Codes/PA required

	for intramuscular use			
90586	Bacillus Calmette-Guerin vaccine (BCG) for bladder cancer, live, for intravesical use	Medicaid & Marketplace	Healthcare Administered Drugs	Addition of Codes/PA required
A9604	Samarium sm-153 lexidronam, therapeutic, per treatment dose, up to 150 millicuries	Medicaid & Marketplace	Healthcare Administered Drugs	Addition of Codes/PA required
A9606	Radium ra-223 dichloride, therapeutic, per microcurie	Medicaid & Marketplace	Healthcare Administered Drugs	Addition of Codes/PA required
J0122	Injection, eravacycline, 1 mg	Medicaid & Marketplace	Healthcare Administered Drugs	Addition of Codes/PA required
J0285	Injection, amphotericin b, 50 mg	Medicaid & Marketplace	Healthcare Administered Drugs	Addition of Codes/PA required
J0642	Injection, levoleucovorin (khapzory), 0.5 mg	Medicaid & Marketplace	Healthcare Administered Drugs	Addition of Codes/PA required
J0712	Injection, ceftaroline fosamil, 10 mg	Medicaid & Marketplace	Healthcare Administered Drugs	Addition of Codes/PA required
J0882	Injection, darbepoetin alfa, 1 microgram (for esrd on dialysis)	Medicaid & Marketplace	Healthcare Administered Drugs	Addition of Codes/PA required
J0887	Injection, epoetin beta, 1 microgram, (for esrd on dialysis)	Medicaid & Marketplace	Healthcare Administered Drugs	Addition of Codes/PA required
J1190	Injection, dexrazoxane hydrochloride, per 250 mg	Medicaid & Marketplace	Healthcare Administered Drugs	Addition of Codes/PA required
J2407	Injection, oritavancin, 10 mg	Medicaid & Marketplace	Healthcare Administered Drugs	Addition of Codes/PA required
J2770	Injection, quinupristin/dalfopristin, 500 mg (150/350)	Medicaid & Marketplace	Healthcare Administered Drugs	Addition of Codes/PA required
J7336	Capsaicin 8% patch, per square centimeter	Medicaid & Marketplace	Healthcare Administered Drugs	Addition of Codes/PA required
J8560	ETOPOSIDE; ORAL, 50 MG	Medicaid & Marketplace	Healthcare Administered Drugs	Addition of Codes/PA required
J9060	INJECTION, CISPLATIN, POWDER OR SOLUTION, 10 MG	Medicaid & Marketplace	Healthcare Administered Drugs	Addition of Codes/PA required

J9100	INJECTION, CYTARABINE, 100 MG	Medicaid & Marketplace	Healthcare Administered Drugs	Addition of Codes/PA required
J9181	INJECTION, ETOPOSIDE, 10 MG	Medicaid & Marketplace	Healthcare Administered Drugs	Addition of Codes/PA required
J9209	INJECTION MESNA, 200 MG	Medicaid & Marketplace	Healthcare Administered Drugs	Addition of Codes/PA required
J9320	INJECTION, STREPTOZOCIN, 1 GRAM	Medicaid & Marketplace	Healthcare Administered Drugs	Addition of Codes/PA required
J9370	VINCRISTINE SULFATE, 1 MG	Medicaid & Marketplace	Healthcare Administered Drugs	Addition of Codes/PA required
Q2017	INJECTION, TENIPOSIDE, 50 MG	Medicaid & Marketplace	Healthcare Administered Drugs	Addition of Codes/PA required
Q2049	INJECTION, DOXORUBICIN HYDROCHLORIDE, LOPOSOMAL, IMPORTED LIPODOX, 10 MG	Medicaid & Marketplace	Healthcare Administered Drugs	Addition of Codes/PA required
Q4081	INJECTION, EPOETIN ALFA, 100 UNITS (FOR ESRD ON DIALYSIS)	Medicaid & Marketplace	Healthcare Administered Drugs	Addition of Codes/PA required
Q5105	INJECTION, EPOETIN ALFA, BIOSIMILAR, (RETACRIT) (FOR ESRD ON DYALYSIS), 100 UNITS	Medicaid & Marketplace	Healthcare Administered Drugs	Addition of Codes/PA required
Q5106	INJECTION, EPOETIN ALFA, BIOSIMILAR, (RETACRIT) (FOR ESRD ON DYALYSIS), 100 UNITS	Medicaid & Marketplace	Healthcare Administered Drugs	Addition of Codes/PA required
Q5116	INJECTION TRASTUZUMAB-QYYP BIOSIMILAR 10 MG	Medicaid & Marketplace	Healthcare Administered Drugs	Addition of Codes/PA required
S0148	INJECTION, PEGYLATED INTERFERON ALFA-2B, 10MCG	Medicaid & Marketplace	Healthcare Administered Drugs	Addition of Codes/PA required
B4187	Omegaven, 10 g lipids	All Lines of Business	Healthcare Administered Drugs	Addition of Codes/PA required
C9054	Injection, lefamulin (Xenleta), 1 mg	All Lines of Business	Healthcare Administered Drugs	Addition of Codes/PA required

C9055	Injection, brexanolone, 1 mg	All Lines of Business	Healthcare Administered Drugs	Addition of Codes/PA required
J0179	INJECTION, BROLUZUMAB-DBLL, 1MG	All Lines of Business	Healthcare Administered Drugs	Addition of Codes/PA required
J9099	BLOOD COMPONENT OR PRODUCT NOT OTHERWISE SPECIFIED	All Lines of Business	Healthcare Administered Drugs	Addition of Codes/PA required
J9199	INJECTION, GEMCITABINE HYDROCHLORIDE (INFUGEM), 200 MG	All Lines of Business	Healthcare Administered Drugs	Addition of Codes/PA required
J9309	INJECTION, POLATUZUMAB VEDOTIN-PIIQ, 1 MG	All Lines of Business	Healthcare Administered Drugs	Addition of Codes/PA required
C9043	INJECTION LEVOLEUCOVORIN 1 MG	All Lines of Business	Healthcare Administered Drugs	Deleted Codes
C9047	INJECTION CAPLACIZUMAB-YHDP 1 MG	All Lines of Business	Healthcare Administered Drugs	Deleted Codes
C9408	DEXAMETHASONE LACRIMAL OPHTHALMIC INSERT 0.1 MG	All Lines of Business	Radiation Therapy	Deleted Codes: Replaced by A9590
0205T	IV CATHCORONARY VESSEL GRAFT SPECTROSCOPY EA VSL	All Lines of Business	Experimental & Investigational	Deleted Codes
0206T	CPTR DBS ALYS MLT CYCLS CAR ELEC DTA 2 OR GRT ECG LDS	All Lines of Business	Experimental & Investigational	Deleted Codes
0249T	LIGATION HEMORRHOID BUNDLE W US	All Lines of Business	Experimental & Investigational	Deleted Codes: Replaced by 46948
0341T	QUANT PUPILLOMETRY W INTERP AND REPORT UNILAT BILAT	All Lines of Business	Experimental & Investigational	Deleted Codes
0357T	CRYOPRESERVATION IMMATURE OOCYTE(S)	All Lines of Business	Experimental & Investigational	Deleted Codes
0482T	ABSOLUTE QUAN MYOCARD BLD FLO PET STRESS AND REST	All Lines of Business	Experimental & Investigational	Deleted Codes
19304	MASTECTOMY SUBCUTANEOUS	All Lines of Business	Experimental & Investigational	Deleted Codes
20926	TISSUE GRAFTS OTHER	All Lines of Business	Experimental & Investigational	Deleted Codes

0399T	MYOCARDIAL STRAIN IMAGING QUAN ASSMT	All Lines of Business	Imaging & Special Tests	Deleted Codes: Replaced by 93356
78805	RP LOCLZJ INFLAMMATORY PROCESS LIMITED AREA	All Lines of Business	Imaging & Special Tests	Deleted Codes: Replaced by 78300, 78305, 78306, 78315, 78800, 78801, 78802, 78803, 78830, 78831, 78832
78806	RP LOCLZJ INFLAMMATORY PROCESS WHOLE BODY	All Lines of Business	Imaging & Special Tests	Deleted Codes: Replaced by 78300, 78305, 78306, 78315, 78800, 78801, 78802, 78803, 78830, 78831, 78832
78807	RP LOCLZJ INFLAMMATORY PROCESS TOMOG SPECT	All Lines of Business	Imaging & Special Tests	Deleted Codes: Replaced by 78300, 78305, 78306, 78315, 78800, 78801, 78802, 78803, 78830, 78831, 78832
0254T	- EVASC RPR ILAC ART BIFUR ENDGRFT CATHJRS AND IUNI	All Lines of Business	Experimental & Investigational	Deleted Codes
97127	THERAPEUTIC IVNTJ W FOCUS ON COGNITIVE FUNCTION	All Lines of Business	Behavioral Health, Mental Health, Alcohol & Chemical Dependency Services	Deleted Codes: To report use code 97129
A9590	Iodine I-131, iobenguane, 1 mCi	All Lines of Business	Healthcare administered	
A9604	Samarium sm-153 lexidronam, therapeutic, per treatment dose, up to 150 millicuries	Medicaid & Marketplace	Healthcare Administered Drugs	
A9606	Radium ra-223 dichloride, therapeutic, per microcurie	Medicaid & Marketplace	Healthcare Administered Drugs	
B4187	Omegaven, 10 g lipids	All Lines of Business	Healthcare Administered Drugs	
C1824	Generator, cardiac contractility modulation (implantable)	All Lines of Business	Experimental/investigational	
C1839	Iris prosthesis	All Lines of Business	DME/supplies	
C2596	Probe, image guided, robotic, waterjet ablation	All Lines of Business	Experimental/investigational	
C9054	Injection, lefamulin (Xenleta), 1 mg	All Lines of Business	Healthcare Administered Drugs	
C9055	Injection, brexanolone, 1 mg	All Lines of Business	Healthcare Administered Drugs	
C9757	Laminotomy (hemilaminectomy), with decompression of nerve	All Lines of Business	OP Hosp/Ambulatory Surgery Center Procedures	

	root(s), including partial facetectomy, foraminotomy and excision of herniated intervertebral disc, and repair of annular defect with implantation of bone anchored annular closure device, including annular defect measurement, alignment and sizing assessment, and image guidance; 1 interspace, lumbar			
C9758	Blinded procedure for NYHA Class III/IV heart failure; transcatheter implantation of interatrial shunt or placebo control, including right heart catheterization, transesophageal echocardiography (TEE)/intracardiac echocardiography (ICE), and all imaging with or without guidance (e.g., ultrasound, fluoroscopy), performed in an approved investigational device exemption (IDE) study	All Lines of Business	Experimental/investigational	
E0787	External ambulatory infusion pump, insulin, dosage rate adjustment using therapeutic continuous glucose sensing	All Lines of Business	DME/supplies	
E2398	Wheelchair accessory, dynamic positioning hardware for back	All Lines of Business	DME/supplies	
K1001	Electronic positional obstructive sleep apnea treatment, with sensor, includes all components and accessories, any type	All Lines of Business	DME/supplies-experimental?	
K1002	Cranial electrotherapy stimulation (CES) system, includes all supplies and accessories, any type	All Lines of Business	DME/supplies	
K1003	Whirlpool tub, walk in, portable	All Lines of Business	DME/supplies	
K1004	Low frequency ultrasonic diathermy treatment device for home use, includes all components and accessories	All Lines of Business	DME/supplies	
L2006	Knee-ankle-foot (KAF) device, any material, single or double upright,	All Lines of Business	DME/supplies	

	swing and/or stance phase microprocessor control with adjustability, includes all components (e.g., sensors, batteries, charger), any type activation, with or without ankle joint(s), custom fabricated			
L8033	Nipple prosthesis, custom fabricated, reusable, any material, any type, each	All Lines of Business	DME/supplies	
P9099	Blood component or product not otherwise classified	All Lines of Business	Miscellaneous	
96158	Health behavior intervention, individual, face-to-face; initial 30 minutes	All Lines of Business	Behavioral/Mental Health, Alcohol-Chemical Dependency	new codes - replaces 96152 all MH diagnoses (F codes) should be excluded when billed as the primary dx.
96159	Health behavior intervention, individual, face-to-face; each additional 15 minutes (List separately in addition to code for primary service)	All Lines of Business	Behavioral/Mental Health, Alcohol-Chemical Dependency	new code - must be listed as an add-on with 96158 all MH diagnoses (F codes) should be excluded when billed as the primary dx.
96164	Health behavior intervention, group (2 or more patients), face-to-face; initial 30 minutes	All Lines of Business	Behavioral/Mental Health, Alcohol-Chemical Dependency	new codes - replaces 96153 all MH diagnoses (F codes) should be excluded when billed as the primary dx.
96165	Health behavior intervention, group (2 or more patients), face-to-face; each additional 15 minutes (List separately in addition to code for primary service)	All Lines of Business	Behavioral/Mental Health, Alcohol-Chemical Dependency	new code - must be listed as an add-on with 96154 all MH diagnoses (F codes) should be excluded when billed as the primary dx.
96167	Health behavior intervention, family (with the patient present), face-to-face; initial 30 minutes	All Lines of Business	Behavioral/Mental Health, Alcohol-Chemical Dependency	new codes - replaces 96154 all MH diagnoses (F codes) should be excluded when billed as the primary dx.
96168	Health behavior intervention, family (with the patient present), face-to-face; each additional 15 minutes (List separately in addition to code for primary service)	All Lines of Business	Behavioral/Mental Health, Alcohol-Chemical Dependency	new code - must be listed as an add-on with 96167 all MH diagnoses (F codes) should be excluded when billed as the primary dx.
96170	Health behavior intervention, family (without the patient present), face-to-face; initial 30 minutes	All Lines of Business	Behavioral/Mental Health, Alcohol-Chemical Dependency	new codes - replaces 96155 all MH diagnoses (F codes) should be excluded when billed as the primary dx.
96171	Health behavior intervention, family (without the patient present), face-to-face; each additional 15 minutes (List separately in addition to code for primary service)	All Lines of Business	Behavioral/Mental Health, Alcohol-Chemical Dependency	new code - must be listed as an add-on with 96170 all MH diagnoses (F codes) should be excluded when billed as the primary dx.

97129	Therapeutic interventions that focus on cognitive function (eg, attention, memory, reasoning, executive function, problem solving, and/or pragmatic functioning) and compensatory strategies to manage the performance of an activity (eg, managing time or schedules, initiating, organizing, and sequencing tasks), direct (one-on-one) patient contact; initial 15 minutes	All Lines of Business	Physical and/or Occupational Therapy	
97130	Therapeutic interventions that focus on cognitive function (eg, attention, memory, reasoning, executive function, problem solving, and/or pragmatic functioning) and compensatory strategies to manage the performance of an activity (eg, managing time or schedules, initiating, organizing, and sequencing tasks), direct (one-on-one) patient contact; each additional 15 minutes (List separately in addition to code for primary procedure)	All Lines of Business	Physical and/or Occupational Therapy	
0139U	Neurology (autism spectrum disorder [ASD]), quantitative measurements of 6 central carbon metabolites (ie, a-ketoglutarate, alanine, lactate, phenylalanine, pyruvate, and succinate), LC-MS/MS, plasma, algorithmic analysis with result reported as negative or positive (with metabolic subtypes of ASD)	All Lines of Business	Behavioral/Mental Health, Alcohol-Chemical Dependency	
0140U	Infectious disease (fungi), fungal pathogen identification, DNA (15 fungal targets), blood culture, amplified probe technique, each target reported as detected or not detected	All Lines of Business	Genetic Counseling & Testing	
0141U	Infectious disease (bacteria and fungi), gram-positive organism identification and drug resistance element	All Lines of Business	Genetic Counseling & Testing	

	detection, DNA (20 gram-positive bacterial targets, 4 resistance genes, 1 pan gram-negative bacterial target, 1 pan Candida target), blood culture, amplified probe technique, each target reported as detected or not detected			
0142U	Infectious disease (bacteria and fungi), gram-negative bacterial identification and drug resistance element detection, DNA (21 gram-negative bacterial targets, 6 resistance genes, 1 pan gram-positive bacterial target, 1 pan Candida target), amplified probe technique, each target reported as detected or not detected	All Lines of Business	Genetic Counseling & Testing	
0143U	Drug assay, definitive, 120 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments including sample validation, per date of service	All Lines of Business	Genetic Counseling & Testing	
0144U	Drug assay, definitive, 160 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments including sample validation, per date of service	All Lines of Business	Genetic Counseling & Testing	
0145U	Drug assay, definitive, 65 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite	All Lines of Business	Genetic Counseling & Testing	

	description, comments including sample validation, per date of service			
0146U	Drug assay, definitive, 80 or more drugs or metabolites, urine, by quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments including sample validation, per date of service	All Lines of Business	Genetic Counseling & Testing	
0147U	Drug assay, definitive, 85 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments including sample validation, per date of service	All Lines of Business	Genetic Counseling & Testing	
0148U	Drug assay, definitive, 100 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments including sample validation, per date of service	All Lines of Business	Genetic Counseling & Testing	
0149U	Drug assay, definitive, 60 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments including sample validation, per date of service	All Lines of Business	Genetic Counseling & Testing	

0150U	Drug assay, definitive, 120 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments including sample validation, per date of service	All Lines of Business	Genetic Counseling & Testing	
0151U	Infectious disease (bacterial or viral respiratory tract infection), pathogen specific nucleic acid (DNA or RNA), 33 targets, real-time semi-quantitative PCR, bronchoalveolar lavage, sputum, or endotracheal aspirate, detection of 33 organismal and antibiotic resistance genes with limited semi-quantitative results	All Lines of Business	Genetic Counseling & Testing	
0152U	Infectious disease (bacteria, fungi, parasites, and DNA viruses), DNA, PCR and next-generation sequencing, plasma, detection of >1,000 potential microbial organisms for significant positive pathogens	All Lines of Business	Genetic Counseling & Testing	
0153U	Oncology (breast), mRNA, gene expression profiling by next-generation sequencing of 101 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a triple negative breast cancer clinical subtype(s) with information on immune cell involvement	All Lines of Business	Genetic Counseling & Testing	
0154U	FGFR3 (fibroblast growth factor receptor 3) gene analysis (ie, p.R248C [c.742C>T], p.S249C [c.746C>G], p.G370C [c.1108G>T], p.Y373C [c.1118A>G], FGFR3-TACC3v1, and FGFR3-TACC3v3)	All Lines of Business	Genetic Counseling & Testing	
0155U	PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase,	All Lines of Business	Genetic Counseling & Testing	

	catalytic subunit alpha) (eg, breast cancer) gene analysis (ie, p.C420R, p.E542K, p.E545A, p.E545D [g.1635G>T only], p.E545G, p.E545K, p.Q546E, p.Q546R, p.H1047L, p.H1047R, p.H1047Y)			
0156U	Copy number (eg, intellectual disability, dysmorphology), sequence analysis	All Lines of Business	Genetic Counseling & Testing	
0157U	APC (APC regulator of WNT signaling pathway) (eg, familial adenomatous polyposis [FAP]) mRNA sequence analysis (List separately in addition to code for primary procedure)	All Lines of Business	Genetic Counseling & Testing	
0158U	MLH1 (mutL homolog 1) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) mRNA sequence analysis (List separately in addition to code for primary procedure)	All Lines of Business	Genetic Counseling & Testing	
0159U	MSH2 (mutS homolog 2) (eg, hereditary colon cancer, Lynch syndrome) mRNA sequence analysis (List separately in addition to code for primary procedure)	All Lines of Business	Genetic Counseling & Testing	
0160U	MSH6 (mutS homolog 6) (eg, hereditary colon cancer, Lynch syndrome) mRNA sequence analysis (List separately in addition to code for primary procedure)	All Lines of Business	Genetic Counseling & Testing	
0161U	PMS2 (PMS1 homolog 2, mismatch repair system component) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) mRNA sequence analysis (List separately in addition to code for primary procedure)	All Lines of Business	Genetic Counseling & Testing	
0162U	Hereditary colon cancer (Lynch syndrome), targeted mRNA sequence analysis panel (MLH1, MSH2, MSH6, PMS2) (List separately in addition to code for primary procedure)	All Lines of Business	Genetic Counseling & Testing	

0563T	Evacuation of meibomian glands, using heat delivered through wearable, open-eye eyelid treatment devices and manual gland expression, bilateral	All Lines of Business	Experimental/Investigational	
0564T	Oncology, chemotherapeutic drug cytotoxicity assay of cancer stemcells (CSCs), from cultured CSCs and primary tumor cells, categorical drug response reported based on percent of cytotoxicity observed, a minimum of 14 drugs or drug combinations	All Lines of Business	Experimental/Investigational	
0565T	Autologous cellular implant derived from adipose tissue for the treatment of osteoarthritis of the knees; tissue harvesting and cellular implant creation	All Lines of Business	Experimental/Investigational	
0566T	Autologous cellular implant derived from adipose tissue for the treatment of osteoarthritis of the knees; injection of cellular implant into knee joint including ultrasound guidance, unilateral	All Lines of Business	Experimental/Investigational	
0567T	Permanent fallopian tube occlusion with degradable biopolymer implant, transcervical approach, including transvaginal ultrasound	All Lines of Business	Experimental/Investigational	
0568T	Introduction of mixture of saline and air for sonosalpingography to confirm occlusion of fallopian tubes, transcervical approach, including transvaginal ultrasound and pelvic ultrasound	All Lines of Business	Experimental/Investigational	
0569T	Transcatheter tricuspid valve repair, percutaneous approach; initial prosthesis	All Lines of Business	Experimental/Investigational	
0570T	Transcatheter tricuspid valve repair, percutaneous approach; each additional prosthesis during same session (List separately in addition to code for primary procedure)	All Lines of Business	Experimental/Investigational	

0571T	Insertion or replacement of implantable cardioverter-defibrillator system with substernal electrode(s), including all imaging guidance and electrophysiological evaluation (includes defibrillation threshold evaluation, induction of arrhythmia, evaluation of sensing for arrhythmia termination, and programming or reprogramming of sensing or therapeutic parameters), when performed	All Lines of Business	Experimental/Investigational	
0572T	Insertion of substernal implantable defibrillator electrode	All Lines of Business	Experimental/Investigational	
0573T	Removal of substernal implantable defibrillator electrode	All Lines of Business	Experimental/Investigational	
0574T	Repositioning of previously implanted substernal implantable defibrillator-pacing electrode	All Lines of Business	Experimental/Investigational	
0575T	Programming device evaluation (in person) of implantable cardioverter-defibrillator system with substernal electrode, with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional	All Lines of Business	Experimental/Investigational	
0576T	Interrogation device evaluation (in person) of implantable cardioverter-defibrillator system with substernal electrode, with analysis, review and report by a physician or other qualified health care professional, includes connection, recording and disconnection per patient encounter	All Lines of Business	Experimental/Investigational	
0577T	Electrophysiological evaluation of implantable cardioverter-defibrillator system with substernal electrode (includes defibrillation threshold	All Lines of Business	Experimental/Investigational	

	evaluation, induction of arrhythmia, evaluation of sensing for arrhythmia termination, and programming or reprogramming of sensing or therapeutic parameters)			
0578T	Interrogation device evaluation(s) (remote), up to 90 days, substernal lead implantable cardioverter-defibrillator system with interim analysis, review(s) and report(s) by a physician or other qualified health care professional	All Lines of Business	Experimental/Investigational	
0579T	Interrogation device evaluation(s) (remote), up to 90 days, substernal lead implantable cardioverter-defibrillator system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results	All Lines of Business	Experimental/Investigational	
0580T	Removal of substernal implantable defibrillator pulse generator only	All Lines of Business	Experimental/Investigational	
0581T	Ablation, malignant breast tumor(s), percutaneous, cryotherapy, including imaging guidance when performed, unilateral	All Lines of Business	Experimental/Investigational	
0582T	Transurethral ablation of malignant prostate tissue by high-energy water vapor thermotherapy, including intraoperative imaging and needle guidance	All Lines of Business	Experimental/Investigational	
0583T	Tympanostomy (requiring insertion of ventilating tube), using an automated tube delivery system, iontophoresis local anesthesia	All Lines of Business	Experimental/Investigational	
0584T	Islet cell transplant, includes portal vein catheterization and infusion, including all imaging, including guidance, and radiological supervision and interpretation, when performed; percutaneous	All Lines of Business	Experimental/Investigational/ Transplant	
0585T	Islet cell transplant, includes portal vein catheterization and infusion, including all	All Lines of Business	Experimental/Investigational/ Transplant	

	imaging, including guidance, and radiological supervision and interpretation, when performed; laparoscopic			
0586T	Islet cell transplant, includes portal vein catheterization and infusion, including all imaging, including guidance, and radiological supervision and interpretation, when performed; open	All Lines of Business	Experimental/Investigational/Transplant	
0587T	Percutaneous implantation or replacement of integrated single device neurostimulation system including electrode array and receiver or pulse generator, including analysis, programming, and imaging guidance when performed, posterior tibial nerve	All Lines of Business	Experimental/Investigational	
0588T	Revision or removal of integrated single device neurostimulation system including electrode array and receiver or pulse generator, including analysis, programming, and imaging guidance when performed, posterior tibial nerve	All Lines of Business	Experimental/Investigational	
0589T	Electronic analysis with simple programming of implanted integrated neurostimulation system (eg, electrode array and receiver), including contact group(s), amplitude, pulse width, frequency (Hz), on/off cycling, burst, dose lockout, patient-selectable parameters, responsive neurostimulation, detection algorithms, closed-loop parameters, and passive parameters, when performed by physician or other qualified health care professional, posterior tibial nerve, 1-3 parameters	All Lines of Business	Experimental/Investigational	
0590T	Electronic analysis with complex programming of implanted integrated neurostimulation system	All Lines of Business	Experimental/Investigational	

	(eg, electrode array and receiver), including contact group(s), amplitude, pulse width, frequency (Hz), on/off cycling, burst, dose lockout, patient-selectable parameters, responsive neurostimulation, detection algorithms, closed-loop parameters, and passive parameters, when performed by physician or other qualified health care professional, posterior tibial nerve, 4 or more parameters			
15769	Grafting of autologous soft tissue, other, harvested by direct excision (eg, fat, dermis, fascia)	All Lines of Business	OP Hosp/Amb Surgery Center (ASC) Procedures	
15771	Grafting of autologous fat harvested by liposuction technique to trunk, breasts, scalp, arms, and/or legs; 50 cc or less injectate	All Lines of Business	OP Hosp/Amb Surgery Center (ASC) Procedures	
15772	Grafting of autologous fat harvested by liposuction technique to trunk, breasts, scalp, arms, and/or legs; each additional 50 cc injectate, or part thereof (List separately in addition to code for primary procedure)	All Lines of Business	OP Hosp/Amb Surgery Center (ASC) Procedures	
15773	Grafting of autologous fat harvested by liposuction technique to face, eyelids, mouth, neck, ears, orbits, genitalia, hands, and/or feet; 25 cc or less injectate	All Lines of Business	OP Hosp/Amb Surgery Center (ASC) Procedures	
15774	Grafting of autologous fat harvested by liposuction technique to face, eyelids, mouth, neck, ears, orbits, genitalia, hands, and/or feet; each additional 25 cc injectate, or part thereof (List separately in addition to code for primary procedure)	All Lines of Business	OP Hosp/Amb Surgery Center (ASC) Procedures	
20560	Needle insertion(s) without injection(s); 1 or 2 muscle(s)	All Lines of Business	OP Hosp/Amb Surgery Center (ASC) Procedures	
20561	Needle insertion(s) without injection(s); 3 or more muscles	All Lines of Business	OP Hosp/Amb Surgery Center (ASC) Procedures	

21601	Excision of chest wall tumor including rib(s)	All Lines of Business	OP Hosp/Amb Surgery Center (ASC) Procedures	
21602	Excision of chest wall tumor involving rib(s), with plastic reconstruction; without mediastinal lymphadenectomy	All Lines of Business	OP Hosp/Amb Surgery Center (ASC) Procedures	
21603	Excision of chest wall tumor involving rib(s), with plastic reconstruction; with mediastinal lymphadenectomy	All Lines of Business	OP Hosp/Amb Surgery Center (ASC) Procedures	
46948	Hemorrhoidectomy, internal, by transanal hemorrhoidal dearterialization, 2 or more hemorrhoid columns/groups, including ultrasound guidance, with mucopexy, when performed	All Lines of Business	OP Hosp/Amb Surgery Center (ASC) Procedures	
64451	Injection(s), anesthetic agent(s) and/or steroid; nerves innervating the sacroiliac joint, with image guidance (ie, fluoroscopy or computed tomography)	All Lines of Business	Pain Management Procedures	
64454	Injection(s), anesthetic agent(s) and/or steroid; genicular nerve branches, including imaging guidance, when performed	All Lines of Business	Pain Management Procedures	
64624	Destruction by neurolytic agent, genicular nerve branches including imaging guidance, when performed	All Lines of Business	Pain Management Procedures	
64625	Radiofrequency ablation, nerves innervating the sacroiliac joint, with image guidance (ie, fluoroscopy or computed tomography)	All Lines of Business	Pain Management Procedures	
78429	Myocardial imaging, positron emission tomography (PET), metabolic evaluation study (including ventricular wall motion[s] and/or ejection fraction[s], when performed), single study; with concurrently acquired computed tomography transmission scan	All Lines of Business	Imaging & Special Tests	

78430	Myocardial imaging, positron emission tomography (PET), perfusion study (including ventricular wall motion[s] and/or ejection fraction[s], when performed); single study, at rest or stress (exercise or pharmacologic), with concurrently acquired computed tomography transmission scan	All Lines of Business	Imaging & Special Tests	
78431	Myocardial imaging, positron emission tomography (PET), perfusion study (including ventricular wall motion[s] and/or ejection fraction[s], when performed); multiple studies at rest and stress (exercise or pharmacologic), with concurrently acquired computed tomography transmission scan	All Lines of Business	Imaging & Special Tests	
78432	Myocardial imaging, positron emission tomography (PET), combined perfusion with metabolic evaluation study (including ventricular wall motion[s] and/or ejection fraction[s], when performed), dual radiotracer (eg, myocardial viability);	All Lines of Business	Imaging & Special Tests	
78433	Myocardial imaging, positron emission tomography (PET), combined perfusion with metabolic evaluation study (including ventricular wall motion[s] and/or ejection fraction[s], when performed), dual radiotracer (eg, myocardial viability); with concurrently acquired computed tomography transmission scan	All Lines of Business	Imaging & Special Tests	
78830	Radiopharmaceutical localization of tumor, inflammatory process or distribution of radiopharmaceutical agent(s) (includes vascular flow and blood pool imaging, when performed); tomographic (SPECT) with	All Lines of Business	Imaging & Special Tests	

	concurrently acquired computed tomography (CT) transmission scan for anatomical review, localization and determination/detection of pathology, single area (eg, head, neck, chest, pelvis), single day imaging			
78831	Radiopharmaceutical localization of tumor, inflammatory process or distribution of radiopharmaceutical agent(s) (includes vascular flow and blood pool imaging, when performed); tomographic (SPECT), minimum 2 areas (eg, pelvis and knees, abdomen and pelvis), single day imaging, or single area imaging over 2 or more days	All Lines of Business	Imaging & Special Tests	
78832	Radiopharmaceutical localization of tumor, inflammatory process or distribution of radiopharmaceutical agent(s) (includes vascular flow and blood pool imaging, when performed); tomographic (SPECT) with concurrently acquired computed tomography (CT) transmission scan for anatomical review, localization and determination/detection of pathology, minimum 2 areas (eg, pelvis and knees, abdomen and pelvis), single day imaging, or single area imaging over 2 or more days	All Lines of Business	Imaging & Special Tests	
81277	Cytogenomic neoplasia (genome-wide) microarray analysis, interrogation of genomic regions for copy number and loss-of-heterozygosity variants for chromosomal abnormalities	All Lines of Business	Genetic Counseling & Testing	
81307	PALB2 (partner and localizer of BRCA2) (eg, breast and pancreatic cancer) gene analysis; full gene sequence	All Lines of Business	Genetic Counseling & Testing	

81308	PALB2 (partner and localizer of BRCA2) (eg, breast and pancreatic cancer) gene analysis; known familial variant	All Lines of Business	Genetic Counseling & Testing	
81309	PIK3CA (phosphatidylinositol-4, 5-biphosphate 3-kinase, catalytic subunit alpha) (eg, colorectal and breast cancer) gene analysis, targeted sequence analysis (eg, exons 7, 9, 20)	All Lines of Business	Genetic Counseling & Testing	
81522	Oncology (breast), mRNA, gene expression profiling by RT-PCR of 12 genes (8 content and 4 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence risk score	All Lines of Business	Genetic Counseling & Testing	
81542	Oncology (prostate), mRNA, microarray gene expression profiling of 22 content genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as metastasis risk score	All Lines of Business	Genetic Counseling & Testing	
81552	Oncology (uveal melanoma), mRNA, gene expression profiling by real-time RT-PCR of 15 genes (12 content and 3 housekeeping), utilizing fine needle aspirate or formalin-fixed paraffin-embedded tissue, algorithm reported as risk of metastasis	All Lines of Business	Genetic Counseling & Testing	
90291	Cytomegalovirus immune globulin (CMV-IgIV), human, for intravenous use	All Lines of Business	Healthcare Administered Drugs	
90371	Hepatitis B immune globulin (HBIG), human, for intramuscular use	All Lines of Business	Healthcare Administered Drugs	
90586	Bacillus Calmette-Guerin vaccine (BCG) for bladder cancer, live, for intravesical use	All Lines of Business	Healthcare Administered Drugs	

The process for obtaining prior authorization **has not** changed. Please complete the Prior Authorization/ Service Request Form with all pertinent information and medical notes as applicable. Service Request Form is available on the Molina Healthcare website under

Provider and under Forms. (<https://www.molinahealthcare.com/members/tx/en-US/health-care-professionals/Pages/home.aspx>)